Life Science Partner recruits former Lead Director of Clinical Affairs at Boston Scientific Cardiac Rhythm Management Division.
Life Science Partner announces the recruitment of clinical affairs executive Steve McQuillan to Medtronic’s Cardiac Rhythm Disease Management Division (CRDM), the largest and oldest business unit of the global $13.5 billion medical device company. With the recent acquisitions of Ablation Frontiers and CryoCath Technologies, the newly formed CRDM Business Unit, AF Solutions, brings breakthrough therapeutic choices and tools to physicians and their patients with atrial fibrillation.
In his most recent role at Boston Scientific Cardiac Rhythm Management (CRM) Division, McQuillan was responsible for developing and implementing the CRM and Electrophysiology clinical strategy for all US-based clinical trials. He had a steady and successful rise through his tenure at the Guidant CRM organization prior joining Boston Scientific. In his new role, McQuillan will provide strategic leadership, oversight, and overall management of the regulatory and clinical activities for the new atrial fibrillation division.
“McQuillan is a passionate, highly motivated executive with wide-ranging clinical and regulatory experience in the CRM space” noted Tom Callaway, MD, founder and president of Life Science Partner. “Along with his strong relationships with Electrophysiology thought-leaders worldwide, he will bring strong clinical development leadership and quality execution to Medtronic’s CRDM Division.”
McQuillan received his Bachelor of Arts Degree in Biometry and Statistics from the University of Minnesota, Twin Cities.